CT-based body composition in diffuse large B cell lymphoma patients: changes after treatment and association with survival

被引:5
|
作者
Pirosa, Maria Cristina [1 ,2 ]
Esposito, Fabiana [1 ]
Raia, Giorgio [3 ]
Chianca, Vito [3 ]
Cozzi, Andrea [3 ,4 ]
Ruinelli, Lorenzo [5 ,6 ]
Ceriani, Luca [2 ,3 ,7 ]
Zucca, Emanuele [1 ,2 ,7 ]
Del Grande, Filippo [3 ,7 ]
Rizzo, Stefania [3 ,7 ]
机构
[1] Ente Osped Cantonale EOC, Ist Oncol Svizzera Italiana IOSI, Via Osped 1, CH-6500 Bellinzona, Switzerland
[2] Inst Oncol Res IOR, Via Chiesa 5, Bellinzona, Switzerland
[3] Ente Osped Cantonale EOC, Ist Imaging Svizzera Italiana IIMSI, Clin Radiol, Via Tesserete 46, CH-6900 Lugano, Switzerland
[4] Policlin San Donato, Piazza E Malan 2, I-20097 Milan, Italy
[5] Ente Osped Cantonale, ICT Informat & Tecnol Comunicaz, CH-6500 Bellinzona, Switzerland
[6] Ente Osped Cantonale, CTU Clin Trial Unit, CH-6500 Bellinzona, Switzerland
[7] Univ Svizzera Italiana USI, Fac Sci Biomed, Via Buffi 13, CH-6900 Lugano, Switzerland
来源
RADIOLOGIA MEDICA | 2023年 / 128卷 / 12期
关键词
CT; Body composition; Bone mineral density; Non-hodgkin lymphoma; BONE-MINERAL DENSITY; ELDERLY-PATIENTS; CHEMOTHERAPY; OSTEOPOROSIS; RISK; CHOP;
D O I
10.1007/s11547-023-01723-5
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose Primary purpose was to assess changes of bone mineral density (BMD) in diffuse large B cell lymphoma (DLBCL) patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone R-CHOP (like) chemotherapy regimen. Secondary purposes were to assess other body composition features changes and to assess the association of pre-therapy values and their changes over time with survival. Material and methods Patients selected underwent R-CHOP(like) regimen for DLBCL, and underwent PET-CT before and after treatment. Main clinical data collected included body mass index, date of last follow-up, date of progression, and date of death. From the low-dose CT images, BMD was assessed at the L1 level; the other body composition values, including muscle and fat distribution, were assessed at the L3 level by using a dedicated software. Descriptive statistics were reported as median and interquartile range, or frequencies and percentages. Statistical comparisons of body composition variables between pre- and post-treatment assessments were performed using the Wilcoxon matched pairs signed rank test. Non-normal distribution of variables was tested with the Shapiro-Wilk test. For qualitative variables, the Fisher exact test was used. Log rank test was used to compare survival between different subgroups of the study population defined by specific body composition cutoffs. The significance level was set at p < 0.05. Results Eighty-two patients were included. The mean follow-up was 37.5 +/- 21.4 months. A significant difference was found in mean BMD before and after R-CHOP(like) treatment (p < 0.0001). The same trend was observed for mean skeletal muscle area (SMA) (p = 0.004) and mean skeletal muscle index (SMI) (p = 0.006). No significant association was demonstrated between body composition variables, PFS and OS. Conclusion R-CHOP(like) treatment in DLBCL patients was associated with significant reduction of BMD, SMA and SMI.
引用
收藏
页码:1497 / 1507
页数:11
相关论文
共 50 条
  • [21] Tafasitamab for the treatment of patients with diffuse large B-cell lymphoma
    Pirosa, Maria Cristina
    Stathis, Anastasios
    Zucca, Emanuele
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2024, 20 (01)
  • [22] Evaluation of treatment patterns and survival among patients with diffuse large B-cell lymphoma in the USA
    Morrison, Vicki A.
    Shou, Yaping
    Bell, Jill A.
    Hamilton, Laurie
    Ogbonnaya, Augustina
    Raju, Aditya
    Hennenfent, Kristin
    Eaddy, Michael
    Galaznik, Aaron
    FUTURE ONCOLOGY, 2019, 15 (09) : 1021 - 1034
  • [23] Racial differences in treatment and survival in older patients with diffuse large B-cell lymphoma (DLBCL)
    Griffiths, Robert
    Gleeson, Michelle
    Knopf, Kevin
    Danese, Mark
    BMC CANCER, 2010, 10
  • [24] Racial differences in treatment and survival in older patients with diffuse large B-cell lymphoma (DLBCL)
    Robert Griffiths
    Michelle Gleeson
    Kevin Knopf
    Mark Danese
    BMC Cancer, 10
  • [25] Treatment strategies for patients with diffuse large B-cell lymphoma
    Poletto, Stefano
    Novo, Mattia
    Paruzzo, Luca
    Frascione, Pio Manlio Mirko
    Vitolo, Umberto
    CANCER TREATMENT REVIEWS, 2022, 110
  • [26] Impact of body mass index on long term survival of patients with diffuse large B-cell lymphoma after primary treatment with R-CHOP
    Nguyen, T. T.
    Schoening, T.
    Ho, A.
    Witzens-Harig, M.
    ONKOLOGIE, 2013, 36 : 138 - 138
  • [27] Treatment of elderly patients with diffuse large B-cell lymphoma
    Nösslinger T.
    memo - Magazine of European Medical Oncology, 2016, 9 (1) : 8 - 12
  • [28] The association between NADPH oxidase (NOX) polymorphisms with immunohistochemistry and survival in diffuse large B cell lymphoma patients
    Chen, Chao
    Dong, Quan
    Wang, Huiqi
    Dong, Shiqi
    Wang, Shufan
    Lin, Wenxin
    Jia, Chuiming
    Dong, Mei
    Jin, Yan
    Liu, Duo
    ANNALS OF HEMATOLOGY, 2025, 104 (01) : 407 - 420
  • [29] Surveillance Imaging after Autologous Hematopoietic Cell Transplantation Predicts Survival in Patients with Diffuse Large B Cell Lymphoma
    Savani, Malvi
    Gencturk, Mehmet
    Shanley, Ryan
    Cayci, Zuzan
    Wilke, Christopher
    Warlick, Erica D.
    He, Fiona
    Janakiram, Murali
    Weisdorf, Daniel J.
    Brunstein, Claudio G.
    Bachanova, Veronika
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (02) : 272 - 277
  • [30] Treatment Modalities and Survival Outcomes for Sinonasal Diffuse Large B-Cell Lymphoma
    Lehrich, Brandon M.
    Abiri, Arash
    Goshtasbi, Khodayar
    Birkenbeuel, Jack
    Yasaka, Tyler M.
    Papagiannopoulos, Peter
    Tajudeen, Bobby A.
    Brem, Elizabeth A.
    Kuan, Edward C.
    LARYNGOSCOPE, 2021, 131 (11): : E2727 - E2735